Exco InTouch, Pharma’s Only Representative on Sunday Times Hiscox Tech Track 100
News Sep 12, 2015
Exco InTouch celebrates its recognition on the Sunday Times Hiscox Tech Track 100 - which ranks Britain’s fastest growing private technology companies.
Exco InTouch are the only pharmaceutical technology company to be recognized on the list and this achievement is built on the company’s rapid acceleration of turnover - sales have tripled over the last three years, highlighting the company’s strengthening position.
Pharma is now embracing new technology platforms as a result of the success of Exco’s robust offerings. Throughout the last few years, Exco InTouch has used its innovations to modernize patient engagement and data capture solutions for clinical trials and digital health programs globally.
Moreover, with the company having cemented pharma partners in both the US and Europe, and with the market for technology solutions within the clinical research and healthcare markets now rapidly expanding, Exco is set for a sustained period of exponential growth.
Exco InTouch are renowned for a long line of healthcare mobile innovations, most recently in July 2015, the granting of a United States patent for its mDNA® technology - an automated tool that manages patients and their mobile device interactivity in clinical and healthcare programs.
The company, which pioneered the use of mobile technology in the clinical trials industry, increasing retention and compliance through engaging and supporting patients, has single handedly evolved the market through eCOA (electronic Clinical Outcome Assessments), ePRO (electronic Patient Reported Outcomes), BYOD (Bring Your Own Device) and is now defining the full potential of mHealth solutions. Exco sales figures are forecast to expand significantly over the next 12 months and the company now employs over 100 of the world’s best mobile technology experts at its global sites.
Tim Davis, CEO and Founder of Exco InTouch, commented: “The next few years of Exco InTouch’s growth are likely to be even more explosive than we have seen to date; our customers have explicit trust in our solutions and we are supporting them to realize the full scope of potential with these types of technologies. Pharma is well known to be an industry resistant to change and innovation, and for Exco InTouch to have single handedly built, defined and grown a technology sector within this market is truly remarkable.
The potential in this market, however, still has a long, long way to go and you will see Exco bringing increased innovations to pharma, healthcare companies and crucially, patients, over the next 3-5 years. We’re on the cusp of a revolution in this sector and Exco intends to continue to redefine how companies and patients use and engage with technology for the advancement of healthcare.”
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019